Hepatitis C is a liver disease caused by the hepatitis C virus (HCV). Seventy-one million are estimated to be living with the virus, with 72% residing in low- and middle-income countries. According to the WHO, there were 1.75 million new infections in 2015.
New direct-acting antivirals (DAA) that are effective across all major HCV strains can cure millions. Yet, approximately 98,5% of the people infected with HCV are not receiving treatment.
We aim to license new and pipeline pan-genotypic DAAs for generic manufacture. We work with generic partners to speed the development and distribution of new HCV treatments that can eliminate the virus through a short course of oral therapy in regions with a high HCV burden. We signed our first licence for a hepatitis C treatment in 2015. A second licence was signed in November 2018.
The MPP licences for Gilead Sciences, covering tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), benefit people living with HIV as well as people living with chronic hepatitis B, a disease that affects 257 million globally. The majority of people with hepatitis B live in low- and middle-income countries.
 World Health Organization, Hepatitis C Fact Sheet, July 2019 (last accessed on 3 Dec. 2019)
 World Health Organization, Global Hepatitis Report 2017
 World Health Organization, Hepatitis B Fact Sheet, July 2019 (last accessed on 3 Dec. 2019)